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Zyflamend, a polyphenol herbal supplement, includes numerous different 
extracts. This botanical complex has been used as a natural anti-inflammatory due 
to its impact on COX-2. More recently, research has exhibited its potential as an 
anti-cancer agent. Currently, the effects of Zyflamend in non-cancer cells, 
specifically adipocytes, has yet to be explored. Due to Zyflamend’s ability to 
promote activation of AMPK, it may prove relevant to study the potential 
interactions with cells treated with Zyflamend during differentiation, a metabolically 
involved process. This study sought to determine the impact of Zyflamend on non-
cancer cells such as 3T3-L1 adipocytes during differentiation and identify the 
mechanisms involved. Zyflamend was shown to effectively and significantly 
attenuate adipogenesis by downregulating markers of lipogenesis, decreasing 
glucose uptake by downregulating GLUT4, and upregulating hormone-sensitive 
lipases. These effects halted differentiation of 3T3-L1 cells and altered their 
metabolic dynamic. As evidenced in previous research, Zyflamend was found to 
increase phosphorylation AMPK, affecting fatty acid metabolism. Furthermore, an 
upregulation of PKA-regulated lipolysis through pHSLS660 was unexpectedly 
observed. In addition, Zyflamend drastically increased activity of JNK. Through 
investigation of these effects, partial rescue of adipogenesis was observed through 
treatments with PKA inhibitor H89 and AMPK inhibitor BML275; however, the 
presence of JNK inhibitor SP600125 showed the strongest rescue over the effects 




attenuating adipogenesis may be modulated in part by upregulation of JNK and 
PKA. The ability of Zyflamend to attenuate the adipogenesis process suggest a 
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Obesity affects over two thirds of the nation and is associated with 
increased risk of a multitude of comorbidities including cardiovascular disease, 
diabetes, and cancer. Understanding how adipose tissue develops and matures 
is essential to the development of dynamic intervention strategies to counter its 
prevalence. Previous literature has comprehensively explored adipose tissue’s 
ability to store excess energy and regulate metabolic requirements. Addressing 
the mechanisms associated with adipocyte differentiation has made 
adipogenesis a viable target for a variety of therapeutic approaches. While 
current pharmaceuticals tend to combat symptoms of obesity, the safety of these 
medications is often disputed. On the other hand, a growing body of evidence 
suggests that a new era of nutraceuticals may provide health specialists new 
means of treating the disease through the use of phytochemicals. 
 
Overview 
Over the last few decades, the prominent trend in increasing body weight 
has sparked concern for a worldwide obesity epidemic. Obesity has been 
correlated with the prevalence of many other diseases such as cancer, metabolic 
disorders, and other illnesses1. Epidemiological studies during this time have 
sought to identify the relationship obesity may play in these occurrences2. This 
has resulted in an international scientific movement exploring causes and 




“Obesity” is a term coined through the use of the body mass index 
screening tool with a designated value of 30.0 or greater. Although not a clinical 
diagnosis, many health professionals continue to use BMI as a means of 
determining weight status and health risk. It is assessed by calculating weight in 
relation to height, but can be further supported through other direct 
measurements determining overall fat density. These methods may range 
through the use of skin calipers, measuring hydration levels, fatness density via 
densiometers, or through dual energy x-ray absorptiometry (DXA scan). 
In the last forty years, researchers have identified a distinct pathology of 
obesity increasing the interest in potential therapeutic interventions. Improving 
activity levels and decreasing dietary intake have shown the most promising 
evidence in reducing symptoms of obesity, but as cases become more extreme, 
other more severe methods have been considered. These cases have ranged 
from surgical procedures to reduce stomach size, to pharmaceutical alternatives 
that mediate symptoms or alter nutrient absorption. Instead, efforts to find 
alternative effective therapeutic interventions that rely less on pharmaceuticals 






2. Obesity and Health 
Epidemiology and Current Statistics 
The National Health and Nutrition Examination Survey, through the NCHS, 
has conducted a stratified, multistage probability sample of the civilian 
noninstitutionalized population of the United States1. This data focused on the 
prevalence of overweight, obesity, and severe obesity among adults age 20 and 
over between the years of 1960-2016.  According to their findings, 39.8% of 
adults in the United States are currently obese, with 70.1% as overweight or 
obese. Variances in BMI were accounted to include differences among genders, 
ethnicity, demographic, and age. Designated a chronic medical disease state, 
obesity is responsible for a number of comorbidities including cardiovascular 
disease, diabetes, kidney disease, cancer, as well as many other disease related 
deaths and continues to be a spreading epidemic2, 3. 
 
Etiology and Pathophysiology 
The development of obesity can result from behavioral, social, cultural, 
genetic, and physiological factors4. This exposes the pathology of obesity to be 
of complex, multidimensional origins. Occurrence of obesity is dependent on an 
imbalance between dietary intake and energy expenditure. As intake supersedes 
energy requirements, physiological mechanisms occur to store excess energy in 




of adipose tissue is the body’s means of providing energy storage sites in cells 
called adipocytes. Among many other functions, adipocytes are responsible for 
excess energy storage in the form of triglycerides and have the ability to increase 
their volume up to several thousandfold to accommodate excess lipid storage5.  
Many institutes, such as The World Health Organization Consultation on 
Obesity, have focused predominantly on behavioral and environmental factors 
responsible for dramatic increases in dietary intake4. An increase in sedentary 
lifestyles coupled with excessive energy intake has been suggested to be 
primarily responsible for changes in adiposity6-8. Changes in dietary patterns 
contributing to preferences towards sugar-sweetened beverages, high fat, and 
high nutrient dense foods appear to be the culprit in many studies9, 10. Economic 
changes in fast-food and convenience food institutions providing budget-friendly, 
high calorie foods have also contributed to the ease of access of obesity-
promoting foods10. Despite substantial evidence suggesting environmental and 
behavioral influences increase risk of obesity, additional confounding evidence 
has been unable to explain every occurrence. This has supported the paradigm 
shift of research efforts to begin investigating additional genetic, epigenetic, and 
physiologic influences.  
As adipose tissue increases, changes in metabolic function and health 
have been observed in a multitude of studies2. Obesity is a major contributor to 
metabolic dysfunction, resulting in changes to glucose intolerance and insulin 




tissue exhibits endocrine system functions by regulating fat metabolism through 
secreted hormones and growth factors12. In cases of obesity, many studies have 
suggested that dysregulation of hormones may contribute to symptoms that 
perpetuate the disease and increase the risk of comorbidities13. Also known to 
influence organ dysfunction, obesity has been shown to increase prevalence of 
cardiac, liver, intestinal, pulmonary, endocrine and reproductive diseases13.  
In some cases, as increases in adipose deposits occur the body reaches a 
degree of capacity with lipid storage and resorts to adipose deposits in other 
sites. This contributes to diseases such as non-alcoholic fatty liver disease (or 
NAFLD) and other diseases where adipose deposits affect organ health14, 15. 
Exhausted storage of triglycerides in adipocytes prevents adequate clearance of 
circulating fatty acid levels resulting in hypertriglyceridemia and lipotoxicity13. The 
production of inflammatory adipokines, or cytokines secreted by adipocytes, is 
associated with the development of hypertension and changes in endocrine 
secretion. Changes in inflammatory response have displayed coordinated direct 
effects on immune dysfunction, heightening risks of cancer, including 
hepatocellular, esophageal, and colon cancers15, 16. The cumulative and 
accelerating effects of obesity have been profound on modern society and its 
resolution of equally profound significance in improving health worldwide. 
Biology of Adipose Tissue 
In mammals, adipose tissue sites are formed and support excess energy 




in similar ways: through storage of energy. However, they vary in phenotype, 
primary function, and metabolic capacity. The principal role of WAT is as an 
endocrine organ and energy storage site; regulating glucose uptake and 
lipogenesis/lipolysis pathways. WAT’s ability to mobilize lipid deposits makes it 
instrumental in a body system’s metabolic capacity. BAT varies in phenotype by 
exhibiting multiple, smaller lipid droplets and increased numbers of mitochondria 
with uncoupling protein-1 (UCP-1), facilitating heat production by bypassing the 
respiratory chain to ATP synthetase16. The unique metabolic variances between 
the two types has developed a strong interest in the development and regulation 
of BAT due to its potential role in protection against obesity and other metabolic 
disorders. 
Brown and white adipocytes share the ability to expand substantially to 
encapsulate large levels of lipids. The ability of mature adipocytes to swell 
previously lead scientists to believe adipose tissue consisted exclusively of 
adipocytes, however recent studies have shown that adipose tissue has a large 
variability of cell type. Many different types of cells can form vascular stroma 
cells, including pre-adipocytes and macrophages; accounting for 10% of WAT in 
obese individuals17. Other cell types include stem cells, endothelial cells, and the 
presence of neutrophils and lymphocytes. Adipose depots may additionally be 
influenced by the level of inflammation produced from surrounding tissue, 




As the state of obesity progresses, adipose tissue undergoes various 
cellular and structural modelling processes, such as tissue expansion by 
adipocyte hypertrophy and hyperplasia18. Adipocytes can facilitate rapid 
remodeling of the extracellular matrix to allow for tissue expansion improving 
their level of plasticity to retain normal lipid storage19. Research has suggested 
that appropriate WAT plasticity seems to act as a safeguard against metabolic 
disorders20. Improving the plasticity of adipose tissue by increasing its anabolic 
function has been a strong focus for therapeutic strategies. Other focuses have 
investigated “browning”, or the conversion of white adipocytes to acquire more 
phenotypic similarities to brown adipose tissue. This term describes the process 
of increasing the thermogenesis function through recruitment of pre-existing BAT 
activation or BAT differentiation factors21, 22 
 
White Adipose Tissue 
Development Origin of WAT 
White adipose tissue (WAT) coordinates systemic metabolism through 
energy storage and hormone regulation23. The developmental pathway of WAT is 
a dynamic force that responds to homeostatic and external cues. Changes to this 
process have been associated with the development of various disease states 
resulting in hyperglycemia, hyperlipidemia, hypertension, diabetes, liver disease, 




The formation of adipose tissue begins in utero during the peripartum 
period and continues throughout life25. In humans, the first “fat lobules” seem to 
be formed at the head level, around the 14–24th week of gestation26. These 
lobules then progressively appear in the trunk, then in the limbs, and by 28 
weeks they can be detected in all presumptive visceral and subcutaneous WAT 
locations. In rodents, WAT cannot be macroscopically detected during 
embryogenesis and develops mainly after birth, first in the perigonadal and 
subcutaneous depots, and only later in the omental depot27. In humans, 
adipocytes are postulated to arise from mesodermal stem cells typical to the 
adipose tissue stroma28.  These adipose mesenchymal stem cells form pre-
adipocytes. This initial phase known as “determination” is characterized by their 
loss of ability to differentiate into other mesenchymal paths; committing to their 
adipocytic lineage28. Terminal differentiation is then initiated, whereby pre-
adipocytes take on adipocyte characteristics and differentiate into mature white 
adipocytes through cascade events triggered by IGF-1, macrophage colony 
stimulating factor, fatty acids, prostaglandins, and glucocorticoids29. These 
positive stimulators work to activate transcription factors PPARγ and 
CCAAT/enhancer binding protein (C/EBP) known to promote adipogenesis30. 
Although typically the cellular content of adipose tissue is made of 
adipocytes, stromal vasculature fraction of fibroblasts, endothelial cells, 
macrophages and pre-adipocytes, WAT in humans expresses a unique depot-




evidenced in human and mice studies, suggesting a varying developmental 
program adding to the unique heterogeneity of the tissue32. Depot-specific 
adipocyte compositions account for the gene and developmental differences 
found in subcutaneous (SAT) and visceral (VAT) WAT locations. The function of 
VAT is genetically unique to account for different metabolic functions and activity 
in comparison to SAT and even peripheral adipose tissue. VAT is comprised of 
intraperitoneal (including omental, mesenteric, and umbilical), extraperitoneal 
(peripancreatic and perirenal), and intrapelvic (gonadal, urogenital) adipose 
tissue. These anatomic locations are associated with increased metabolic 
activity, compared to subcutaneous (truncal, mammary, gluteofemoral) adipose 
tissue depots73.  
In addition, a preference for depot sites has been reported between 
genders; women tend to accumulate fat around peripheral and subcutaneous 
depots resulting in a “gynoid” distribution. Conversely, men have increased 
visceral depot deposits representing an “android” distribution33. Although women 
typically present a higher fat mass by roughly 10% in comparison to men, the 
distribution of the fat mass seems to alleviate the influence of the risk in 
associated diseases34. Sex hormones are responsible in modulating this 
distribution with estrogen levels supportive of fat mass accumulation in the 
femoral-gluteal subcutaneous depots. Additionally, stress hormones such as 
glucocorticoids have been found to induce fat accumulation in neck and upper 




linking glucocorticoids to Cushing’s syndrome, impaired peripheral glucose 
uptake, dysregulated blood pressure and obesity34, 36. 
Distinctive consequences are associated with each adiposity distribution 
between depots. It is important to note that there is clinical evidence supporting 
that increased visceral adipose tissue depots relate to increased risk factors of 
type 2 diabetes, hypertension, and lipidemia32. This may account for the 
increased prevalence of men exhibiting symptoms of metabolic and 
cardiovascular disease in comparison to women of similar age. Alternatively, 
increased SAT accumulation has been shown to intensify coronary heart disease 
(CHD) and peripheral vascular disease risk37. 
Varying levels of bioactive molecules and their influence on enzymatic 
processes associated with fat metabolism have also been reported between SAT 
and VAT. Intrinsic differences in various gene expression levels, such as 
increased expression of Shox2, En1, HoxC9 and Gpc4 have been found in 
subcutaneous depots31. In addition, visceral depots expressed higher 
transcription of genes Sfrp2, Nr2f1, Thbd, HoxA5, HoxC8 and Tbx1531. These 
differences are not concentrated to variances solely between subcutaneous and 
visceral locations, but seem to continue across other anatomical locations, 
although the relationship between VAT and SAT has been heavily investigated 
due to their varying associations with metabolic disease. 
Further distinctions in characteristics include the preference of WAT 




cell size (hypertrophy) and vice versa. As suggested, type of stem/progenitor 
cells expressed in each depot can account for the variances between 
proliferative and adipogenic properties25. Expansion over proliferation can have 
impressive connotations depending on the depot of origination. Adipocyte 
hypertrophy has been shown to have a lesser impact on an altered lipid profile in 
women over adipocyte hyperplasia38. Although these cases may be specific to 
each depot, it has been suggested that a 10% increase in omental adipocytes 
(as part of VAT type depots) increases hyperlipidemia risk 4-fold from baseline, 
whereas enlarged subcutaneous adipocytes failed to significantly alter 
hyperlipidemia risk38. 
To influence this balance between hypertrophy and hyperplasia, growth 
factors in adipocytes are dependent on a strong cross-talk relationship between 
adipose cells to support energy storage demands. Clonal pre-adipocytes, a 
subtype typical of subcutaneous WAT depots, undergo extensive lipid 
accumulation, and express strong replicative and adipogenic characteristics 
resistant to TNF-alpha induced apoptosis39. This tissue seems to express low-
density lipoprotein-related protein (LRP)-5 in the WNT signaling cascade as a 
major regulator for its distribution40. However, visceral depots have markedly 
weaker characteristics in both inheritable and cell-autonomous manners despite 
confirmation of same pre-adipocyte lineage41. These indicators contribute to the 





Genetic and Epigenetic Control of WAT 
As discussed, WAT’s difference in phenotype from BAT originates with its 
own distinct genotype. The differentiation of white adipocytes requires a myriad 
of transcription factors elegantly working together coordinating processes that 
often work with each other. When the conditions are ripe for adipogenesis, the 
sequence is activated through the transcription factor activating protein-1 (AP-1). 
AP-1 triggers the induction of PPARγ; which is essential for trans-differentiation 
of mesenchymal stem cells, or MSC’s, to initiate pro-adipogenic transcription 
factors. To shift toward mature adipocyte differentiation, other transcription 
factors are employed to stimulate, activate, and regulate the process toward 
growth and proliferation.  
 
AP-1  
AP-1 consists of a family of transcription factors including v-Jun, JunB, 
JunD, c-Jun, v-Fos, Fos B, c-Fos, ATF2/3, B-ATF, and Fra1/242. The role of 
these transcription factors is to employ direct interaction with DNA to regulate 
gene expression involved in differentiation and proliferation. Evidence supporting 
the role of AP-1 members and their role in adipocyte differentiation originated 
from research investigating the effects of transgenic mice generated to interrupt 




mice lacking white adipose tissue and elucidated the necessity of AP-1 
transcription factors in adipogenesis43. 
 
WNT 
The wingless-type MMTV integration site family members, or WNT family, 
is responsible for the regulation of adipogenesis and is comprised of 19 secreted 
glycoproteins that mediate adult tissue homeostasis through multiple pathways44. 
These proteins act locally on autocrine and paracrine growth factors and mediate 
cell to cell communication essential for adipocyte maintenance and remodeling 
by repressing adipogenesis when needed45. In experiments disrupting the 
canonical WNT signaling pathway, preventing the convergence of receptors 
Frizzled(Fzd)/LRP-5/6 in stimulating the transcriptional factor ß-Catenin pathway, 
spontaneous adipogenesis occurs, suggesting a strong correlation with WNTs in 
restraining pre-adipocyte differentiation by blocking induction of PPARγ and 
CEBPA46, 47. Adipocyte fate determination and stem/progenitor cell self-renewal 
is associated with this pathway, though conversely, a noncanonical WNT 
pathway can also occur47. The ß-catenin independent noncanonical pathway is 
associated more with regulating crucial events associated with embryonic 
development. It differs from its sister pathway by circumventing its reliance on ß-
catenin and triggering other receptors outside of Fzd; however, little is known 





KLF   
Other transcription factor families interact with zinc-finger DNA domains, 
such as the Kruppel-like family. KLF’s have been implicated in cell development, 
differentiation, and proliferation and display critical roles of gene activation and 
suppression48. To date, 17 members have been identified; in adipogenesis, 
however, KLFs 4, 5, 6, and 15 have proven to be stimulators of adipogenesis49. 
Several studies have identified these factors to be highly expressed in WAT pre-
adipocytes during differentiation and may also contribute to lipid accumulation 
and insulin sensitivity49-51. 
 
C/EBP 
Additionally, consider the role of “leucine zipper” transcription factors in 
the family of CCAAT/enhancer-binding proteins (C/EBPs). Each of the six 
isoforms of C/EBPs serve as an interaction point between sequence-specific 
DNA and bZIP domains connecting other transcription factor families52. Ample 
research has supported the observation that C/EBPs promote adipogenesis. In 
vivo studies have compared the relationship of the various isoforms and their role 
in adipose tissue development. In general, C/EBP deficient mice are marked by 






During an investigatory study by the Speigelman group examining basic 
helix-loop-helix DNA binding proteins, a novel member of these bHLH-leuzine 
zipper transcriptions factors was identified55. Originally termed “adipocyte 
determination and differentiation factor-1” or ADD-1 in mice studies, the human 
homolog was renamed as the sterol response element-binding protein-1, or 
SREBP-156. SREBP’s contain three isoforms (SREBP-1a, -1c, and -2) that 
function as critical factors of adipocyte development that binds to the sterol 
response element in the promoter region of low-density lipoproteins receptors57. 
In vitro studies have shown that point-mutations inhibiting the expression of ADD-
1/SREBP-1 repressed adipocyte marker genes and prevented differentiation58. 
Efforts to mirror results in in vivo studies have been less consistent; transgenic 
mice with SREBP-1 knockout expression developed adipose tissue with limited 
inhibition of adipocyte markers lipoprotein lipase and adipocyte lipid binding 
protein59. Despite other studies conferring that SREBP-1 may not be required for 
adipogenesis, further analysis is necessary to determine its full role in adipose 
tissue proliferation and development60. 
Epigenetic modifications through DNA methylation and histone 
modifications can also result in influential changes to regulating gene 
expressions and shifts in phenotypes influencing states of disease. Gene 
repression has historically been associated with epigenetic changes in the 




physical activity, and type 2 diabetes61. These changes have been associated 
with altered cellular composition of WAT and not necessarily linked to true 
genetic changes to specific cell types62. Typical environmental factors known to 
influence the epigenetics of WAT include decreased/increased physical activity, 
increased/decreased dietary intake, and storage. The epigenetic influence of 
obesity is an expanding topic that may yield insight into disease development 
and prevention. In a study comparing post-obese and never-obese women, a 
series of genes were mapped and compared exposing 8504 demethylation sites. 
Nearly 30% of the genes linked to adipogenesis displayed genetic modifications 
due to DNA methylation63. Other pathways shown to be over-represented 
included pathways linked to cell differentiation (i.e. WNT signaling), apoptosis, 
and autophagy. In this particular study, researchers elucidated 18 adipogenesis 
genes differentially expressed due to increased body fat: IGF1, NCOR2, RARA, 
MEF2D, SREBF1, NRIP1, LIFR, EBF1, GDF10, KLF5, AHR and PLIN263. Other 
genes linked to lipid turnover such as ABCG1, AGPAT4, and ACAD9 were 
shown to have differential gene expression, suggesting common epigenetic 
changes resulted in increases of lipid accumulation and lipid synthesis63. Other 
variances were noted in genes specific to obesity, such as the MRAP2 and 
RCAN2 gene. Interestingly, some epigenetic changes can be reversed upon 
weight loss, although adipocyte cell numbers are not affected. In conclusion, 
epigenetic marks and chromatin-modifying proteins increase adipogenesis and 






The traditional role of adipose tissue is well understood; the storage of 
energy and the release of fatty acids when fuel is required. The extent of the role 
WAT plays in metabolism has proven to be more complex. An evolving concept 
of adipose tissue as an endocrine organ has continued to gain footing, expanding 
on previous interpretations. This includes adipocytes’ ability to sense, manage, 
and send signals to adjust energy equilibrium within the body. This metabolically 
active tissue regulates through endocrine, paracrine, and autocrine signals that 
extends to other organs involved in metabolism regulation (i.e. brain, liver, 
muscles, and pancreas)65. 
WAT’s contributes to lipid metabolism through opposing processes of 
lipogenesis and lipolysis. Lipogenesis is the synthesis of esterified fatty acids to 
form triglycerides from energy sources consumed in the diet. In humans, the liver 
is predominantly responsible for the process in response to a postprandial state 
and the process is inhibited in fasting conditions. Once released, these fatty 
acids are entered into circulation through chylomicrons in their non-esterified 
form and become reliant on adipose tissue uptake for re-esterification and 
eventual lipid storage66. Insulin released during feeding stimulates enzymes 
involved in fatty acid biosynthesis and uptake, including sterol regulating 
element-binding protein (SREBP). Once in the cell, transcription factors 




Perilipin A acts to surround the triglycerides, preventing access of lipases to 
degrade the lipids and ß-adrenergic stimulation of adipocytes induces 
downstream effectors to move and increase lipid droplet accumulation in white 
adipocytes. Lipogenesis is required for proper energy packaging and storage, 
allowing for its counterpart, lipolysis, to have the proper components available for 
degradation. Dysregulation of lipogenesis has been linked to obesity, type 2 
diabetes, and cardiovascular disease. Thus, proper regulation is necessary for 
signaling factors to appropriately balance the flux of lipogenesis and lipolysis 
pathways. 
At times, when mammals experience an increased need of energy 
requirements, adipose tissue responds by appropriating stored fatty acids 
through lipolysis. The innervation of white adipose tissue from the sympathetic 
nervous system works to activate lipolysis through ß-adrenergic factors (i.e. 
epinephrine) to stimulate adipose triglyceride lipase (ATGL), hormone sensitive 
lipase (HSL), and perilipin A phosphorylation67. Epinephrine stimulates cyclic-
AMP-mediated activation of protein kinase A (PKA). PKA phosphorylates ATGL 
as the first responder to hydrolyze triglycerides into diglycerides and fatty acids68. 
Activation of accessory proteins and HSL further hydrolyzes to produce 
monoglycerides and fatty acids. Monoglyceride lipase ends the chain by 
generating glycerol and a third fatty acid69. These key contributors of stored 
triacylglycerol breakdown produce non-esterified fatty acids to be delegated to 




Studies have shown that lipolytic enzymes may be directly inhibited by the 
presence of insulin, suggesting that insulin directly mediates nutritional 
regulation. As with all metabolic processes, relative balance is required to 
prevent dysregulation. Understanding the mechanisms and influences of all 
metabolic systems and their harmonizing relationships with WAT is essential to 
understanding the development and pathophysiology of obesity, diabetes, and 
other metabolic disorders.  
In 1994, Jeffrey Friedman and Douglas Coleman discovered leptin, the 
adipocyte cell-produced hormone that signals to the brain the energy status of 
peripheral tissues71. This discovery seemed to illuminate researchers to the 
potential of a physiological feedback loop controlling energy homeostasis and 
improve the understanding of the genetic and neuroendocrinological potential of 
adipose tissue. As these investigations continued, the ability of adipocytes to 
influence physiological processes through the secretion of adipokines became 
evident. Adipokines, comprised of hormones, cytokines, and other proteins with 
specific biological function, are unique to adipocytes and are involved in energy 
homeostasis, extracellular matrix dissolution and reformation, angiogenesis, 
steroid metabolism, immune response, and hemostasis72, 73. As researchers 
have continued to elucidate the potential of adipokines, adipose tissue has 
expanded its role from excess energy storage to a fundamental participant in 




In recent years, the list of adipokines has expanded rapidly to include 
resistin, adiponectin, apelin, visfatin, retinol-binding protein-4 (RBP-4), serpin, 
lipcalin-2, vaspin, omentin, in addition to inflammatory cytokines TNF-alpha, 
interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1). In order to 
understand some of these functions, a few of these adipokines should be 
discussed.  
Certain adipokines have developed a role in modulating glucose 
intolerance, such as resistin and RBP-4. Resistin acts to induce insulin 
resistance in insulin sensitive tissues such as muscle and adipose tissue and 
may be related to fasting adaptation74. In animal studies, RBP-4 has also been 
shown to decrease insulin sensitivity and seems to be highly expressed in insulin 
resistant obese individuals75. Conversely, adiponectin enhances insulin 
sensitivity and decreases influx of non-esterified fatty acids, increasing oxidation 
in the liver and muscle76. Of interest is adiponectin’s ability to increase 
uncoupling protein 2 (UCP-2) and acyl coenzyme oxidase expression in muscle 
and improving PPARγ expression in adipose tissue76. These genes improve lipid 
catabolism and decrease lipid storage, improving metabolic parameters. Apelin is 
also known to influence obesity by improving cardiovascular function through 
increasing cardiac contractility and lowering blood pressure77. Interestingly, the 
distribution and activation of certain adipokines is dependent upon the location 





Major Signaling Pathways Involved in WAT Adipogenesis 
The differentiation process that supports proliferation is controlled by 
stimuli that can influence adipocyte growth. As mentioned, a variety of ß-
adrenergic factors can activate this process; however, multiple pathways can be 
stimulated. The culmination of these signaling pathways represents regulators 
that can promote and inhibit adipogenesis. For example, the WNT signaling 
pathway has been previously described to be a strong regulator of adipocyte 
differentiation. As a highly conserved signal transduction pathway that plays a 
role in proliferation and differentiation during embryonic development, activation 
of this pathway is essential to communicating stop-signals. In this section, other 
pathways that stimulate this process and key regulators will be explored. 
 
BMP’s 
As described, MSC’s have the ability to differentiate into a variety of cell 
types. The formation into pre-adipocytes can be triggered by members of the 
bone morphogenic protein (BMP) family, or specifically BMP4 and BMP2. The 
presence of BMP4 has been shown to commit pluripotent C2H10T1/2 cells to an 
adipose lineage, confirming the development into the white adipocyte 
phenotype78. Although BMP2 itself has little influence over adipogenesis, it does 




although in some in vitro studies, the TGF-ß signaling cascade has also been 
shown to inhibit adipogenesis by repressing C/EBP’s transcriptional activity78, 79.  
 
MAPK’s 
Mitogen activated protein kinases or MAPK’s represent a family of 
signaling pathways well investigated to have the capacity to influence various cell 
signaling cascades affecting adipogenesis80, 81. A subsection of this family is 
comprised of extracellular signal-regulated kinases (ERKs), which function to 
control cell cycle and regulation of proliferative factors. Other members of this 
family include c-Jun amino-terminal kinases (JNKs) and p38 mitogen activated 
kinases, which have proven to be associated with stress response and apoptotic 
regulation.  
In response to cytokines, osmotic stress, heat shock, fatty acids, and 
growth factors, JNKs can interfere with insulin signaling pathways, promote 
inflammation, induce apoptosis, and effect rates of proliferation82, 83. The direction 
of the cascade events triggered by JNKs is dependent upon the specific stimuli 
and cell-type associated with its activation. Although obesity and metabolic 
disease research has illuminated a complex relationship between apoptotic 
events and inflammation, a pathway illuminating a direct correspondence with 
adipogenic factors has yet to be evidenced.  
Research on p38 has proven to be even more convoluted with studies 




properties. While p38 is well evidenced to be supportive of UCP1 expression in 
BAT, it’s role in differentiation and glucose uptake in WAT has yielded 
controversial results84. For example, considering p38 MAPK inhibitor interactions 
during adipocyte differentiation, results have shown that inhibitors, such as 
SB20350, during pre-adipocyte differentiation decreased the formation of 
adipocytes and downregulated C/EBPß phosphorylation85. Conversely, there is 
evidence that p38 may indirectly inhibit differentiation by phosphorylating 
CHOP10, a member of the C/EBP family. P38 has also been shown to 
phosphorylate nuclear factor of activated T-cells (NFATc4), binding with PPARγ 
to inhibit its expression86. As studies examining the relationship of MAPKs with 
adipogenesis continue to be explored, the development of inhibitory factors 




 AMPK, or AMP-activated protein kinase, is a well-known energy sensor 
that is crucial to energy metabolism and regulation. Although research on AMPK 
is well established, its role in adipose function is still relatively enigmatic. Various 
studies have investigated how AMPK may promote adipocyte browning and 
illuminate its effect on energy homeostasis. Exposure to increased AMPK levels 
during adipogenesis has been shown to inhibit differentiation of WAT, and 




beige adipocytes in 3T3-L1 cells by reducing expression of PRDM1687, 88. AMPK 
has been found to be indispensable to fatty acid metabolism, thermogenesis, and 
development of adipose tissue. Understanding the effect of AMPK on 
adipogenesis will prove to be essential to the future research explored in the 
following manuscript.  
 
3. Therapeutic Approaches 
Standard Methods 
Fewer topics have engendered as much controversy as the health 
concerns associated with excess fat mass. Obesity was once a novel concern. 
Now, obesity rates have extended across nations and populations all around the 
world. A series of chronic conditions have been associated with the development 
of obesity and its influence over metabolism. These conditions have been linked 
to a host of other disorders that include respiratory issues and infertility. In 
summation, as a large-scale analysis of over 1.4 million adults showed, obesity 
was directly linked with an overall increase in mortality89. 
The importance of addressing this growing epidemic with methods to 
reduce instances of obesity need not be argued. Instead, efforts have 
concentrated on determining and evaluating therapies for weight reduction. 
Considering available methods, little more can be said for the effectiveness of 
increased physical activity and monitored dietary intake. Dietary therapies come 




intake to create an energy deficit. Many strategies often employ the reduction of 
saturated fats and carbohydrates90. This method requires patience and 
consistency, as weight reduction often involves time. Obese individuals should 
consider contacting nutritional specialists or seeking counsel to properly follow 
dietary restrictions unique to their needs91. In order to reduce weight, an energy 
deficit of 500/kcal per day is often prescribed, although certain cases may require 
more extreme strategies92. 
Physical activity, often in conjunction with changes in dietary intake, has 
been shown to not only reduce weight, but improve other health parameters 
associated with obesity93. Various forms of physical exercise are available, 
including strength training, circuit training, endurance training, and high intensity 
interval training94. Although each method may be found to have different levels of 
energy expenditure, a mixed approach may provide the best results in combining 
weight reduction and improving overall health. It is suggested that a weight 
reduction of 2 kg within 6-12 months is deemed appropriate95. Though behavior 
and lifestyle modifications continue to be the most effective long-term treatments 
for obesity and weight reduction, dire cases have escalated the necessity for 
more immediate pharmaceutical therapies. Several medications are available 
through over-the-counter and prescription methods. More recognized 
medications include Orlistat, a lipase inhibitor that works to prevent the 
degradation of dietary triglycerides and increases their excretion96. Medications 




of fat-soluble vitamins. Phentermine is a prescription drug that decreases desire 
for food, but does not influence metabolism. Similar pharmaceutical options also 
work to inhibit serotonin, norepinephrine, and dopamine reuptake and influence 
dietary behaviors, though long term use is not advised97. 
Innovative Nutrient Strategies 
For many, the adverse effects of pharmaceuticals perpetuate a sense of 
unease about their safe use. Instead, a growing body of evidence suggests that a 
new era of nutraceuticals may provide health specialists new means of treating 
disease through the use of phytochemicals. Phytochemicals are biologically 
active compounds found in plants that play a role in plant growth or defense 
against pathogens, competitors, or predators98. In clinical studies, 
phytochemicals have shown potential to attenuate oxidative stress and 
inflammation99. 
Traditional use of phytochemicals can be traced back to ancient Chinese 
and Indian medicine where a variety of herbs and fruits were used to treat 
ailments such as infertility, headaches, skin detoxification, and improve eyesight. 
Ancient medicines also proffered therapeutic agents such as diuretics, cough 
expectorants, and treatments for inflammatory disorders100. A variety of 
compounds were used to treat disorders such as diabetes and cardiovascular 
disease and touted hepatoprotective attributes. Current research has collected 
theories from these practices to consider their health value in clinical trials; 




literature is the elevated number of possible compounds investigated and the 
poor means of assessing effective dosage. As an example, a PubMed search of 
the term “phytochemical” alone yields over 25,000 publications with a plethora of 
polyphenols making narrowing options for analysis difficult to determine. Other 
topics of concern include whether researchers should isolate the most bioactive 
compound or consider whole nutrient sources. Decisions among these factors 




Zyflamend is a phytonutrient supplement that includes a variety of different 
herbal extracts104. Containing the extracts from ginger, rosemary, turmeric, 
Chinese goldthread, holy basil, Hu Zhang, barberry, oregano, green tea, and 
Chinese skullcap, Zyflamend was originally developed based on their anti-
inflammatory properties. A review of associated literature has reinforced this 
claim as several compounds found in Zyflamend seem to inhibit the pro-
inflammatory pathways of MAPK’s and transcription factor nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB )105, 106. Studies investigating the 
beneficial potential of phytochemicals tend to focus on large doses of individual 
bioactive ingredients. Alternatively, the therapeutic results of Zyflamend 




studies of Zyflamend have proposed that its robust effects may in part be due to 
the synergistic capacity between ingredients104. 
Currently, research efforts have asserted Zyflamend holds new relevancy 
as a potent anti-cancer therapy107, 108. Although the mechanisms involved are still 
being reviewed, these studies point to a potential influence over genes regulating 
cell cycle and apoptosis107. NF-kB is a protein complex that is involved in 
cytokine production and regulates cell survival through apoptosis inhibition109. 
Previous studies have tied some of the anti-cancer effects of Zyflamend to the 
regulation of NF-kB signaling pathway110.  Recently, new studies have begun to 
investigate how these anti-cancer pathways may interact in non-cancer cells. 
There remains limited evidence on the relevancy of Zyflamend in normal cells as 
its main impact with publications has been through cancer research; yet studies 
have unmasked NF-kB as the primary pathway responsible for inflammation in 
excess adipose tissue111. Further examination of the anti-inflammatory and 
anticancer pathways effected by Zyflamend treatment suggest there may be 
other connections to metabolic dysregulation. Little research has been published 
on this topic, leaving many properties unexplored.  
History 
The first reference of Zyflamend in scientific literature came with Bemis et 
al.’s publication on its nonselective cyclooxygenase-2 (COX-2) inhibition in 
prostate cancer112. This research sparked a procession of studies determining 




Several authors, several studies, several cancers, and several discoveries later 
and Zyflamend research continues to yield therapeutic potential for a variety of 
conditions. 
 
A Review of the Literature 
A review of the scientific literature on Zyflamend emphasizes a focus on 
its therapeutic properties in cancer.  Even so, general mechanistic studies have 
revealed various effects on anti-inflammatory pathways. Several studies have 
suggested that Zyflamend may attenuate inflammation through multiple signaling 
pathways107, 113, 114. Some studies concluded Zyflamend may suppress COX 1/2 
activity, although many studies emphasized inhibition of NF-kB as the major 
pathway of interest, specifically through its primary transcription factor Re1A107, 
113, 115. Suppression of NF-kB resulted in reduction of TNF-alpha and other pro-
inflammatory mediators and improvement of pro-apoptotic events. 
Other studies on Zyflamend’s effect on metabolomics expressed its ability 
to modify cellular energetics. Zyflamend has been shown to activate AMPK in 
vivo116. The mechanisms of AMPK activation suggest an ability to regulate 
specific pathways promoting lipolysis and promoting adipose tissue reduction 
through tumor suppressor liver kinase B-1 (LKB1)104. These preliminary studies 
suggest potential in utilizing Zyflamend in metabolic research. However, 








The ingredients of Zyflamend include ginger, rosemary, turmeric, Chinese 
goldthread, holy basil, Hu Zhang, barberry, oregano, green tea, and Chinese 
skullcap. Many of these herbs are touted for their various anti-diabetic, anti-
cancer, and anti-oxidant benefits. Of the ingredients, several have been shown to 
exhibit anti-inflammatory properties as well. Health specialists have deemed 
obesity a chronic low-grade inflammatory disease13. Research has suggested 
that results of phytochemical supplementation may contribute to decreased 
inflammation attributed to metabolic diseases; however, the translatability to 
clinical trials has much to be desired. This review explores the shift towards 
holistic therapeutic approaches to find increased effectiveness when treating 
metabolic disease. Furthermore, this field is shifting from novel basic science 
research towards real clinical application as the development of phytochemical 





5. Research Objectives 
Specific Aims 
Obesity is a continued global health concern that directly correlates with 
significant health consequences. Prevalence of obesity has been associated with 
a multitude of metabolic disorders like type 2 diabetes mellitus, dyslipidemia, 
cardiovascular disease, hypertension, as well as other physiological disorders 
and injuries like liver dysfunction, cancer, and respiratory disorders. These 
comorbidities are exacerbated by the pro-inflammatory nature of the disease, 
thus, determining potential new therapeutic approaches to decrease adipose 
tissue is vital for more effectively treating obesity. 
Found in a variety of fruits, vegetables, and spices, phytochemicals are 
naturally occurring compounds commonly consumed. These therapeutic 
phytochemicals also use a variety of pathways ranging from increasing the 
efficacy of certain enzymes’ antioxidant activity, posttranslational modification of 
key signaling molecules, and regulation of gene expression4. Zyflamend, an 
herbal supplement has been used standardly as a medicinal anti-inflammatory 
agent. Previous studies have tied the anti-cancer effects of Zyflamend to the 
regulation of the NF-kB signaling pathway and phosphorylation of AMPK 
suggesting that Zyflamend may influence metabolic factors that could provide 
therapeutic treatment to combat obesity. However, certain questions remain 




white adipocytes, and (2) what molecular mechanisms mediate the effectiveness 
of Zyflamend and its influence over adipogenesis? 
The central hypothesis of this study is that Zyflamend supplementation 
attenuates adipogenesis; however, its mechanisms will be determined. 
 
Specific Aim 1: To determine the effects of Zyflamend in vitro on adipocyte 
differentiation using molecular techniques. We will use the well-established 
model that employs 3T3-L1 cells. Through innovative methods, we expect to 









THE CROSS-TALK BETWEEN PKA AND JNK MEDIATES THE 
ANTI-ADIPOGENIC POTENTIAL OF ZYFLAMEND, A UNIQUE 





Zyflamend, a polyphenol herbal supplement, includes numerous different 
extracts. This botanical complex has been used as an anti-inflammatory due to its 
impact on the NF-kB signaling pathway. However, recent research has exhibited 
its potential as an anti-cancer agent by stimulating AMPK and shifting the 
metabolic dynamic in cancer cells. Currently, the effects of Zyflamend in non-
cancer cells has yet to be elucidated. This study sought to explore the interactions 
of Zyflamend treatment on non-cancer cells such as 3T3-L1 adipocytes. The 
results of this study showed that Zyflamend significantly attenuated adipogenesis. 
As evidenced in previous research, Zyflamend was found to increase 
phosphorylation of AMPK and downregulate markers of lipogenesis, decreasing 
glucose uptake and upregulating lipolytic enzymes. It was determined this pathway 
occurred by upregulation of PKA-regulated lipolysis through pHSLS660. In 
addition, Zyflamend drastically increased activity of MAPK activity, specifically 
JNK. Through investigation of these effects, partial rescue of adipogenesis was 
observed through treatments with PKA inhibitor H89 and AMPK inhibitor BML275; 
however JNK inhibitor SP600125 more significantly rescued the effects of 
Zyflamend on differentiation. These results suggest Zyflamend’s effect on 





Zyflamend has been shown to downregulate NF-kB and upregulate AMPK 
activity in cancer cells, resulting in a shift in metabolism that results in cancer cell 
death. AMPK activity is also an essential part of metabolism and can impact the 
differentiation of non-cancer cells. Currently, methods to promote activation of 
AMPK have been used in metabolic research to influence the differentiation of 
adipocytes, primary energy storage cells. By addressing the mechanisms 
associated with adipocyte differentiation, adipogenesis has become a target for a 
variety of therapeutic approaches in metabolic research. Zyflamend’s ability to 
shift energy metabolism and promote energy expenditure may yield therapeutic 







Obesity is a global health concern that directly correlates with significant 
health consequences. Obesity is caused by excessive energy consumption and 
can lead to an increased mortality rate through a variety of comorbidities making 
therapeutic and preventative approaches to these conditions of top interest to 
health professionals118. Type 2 diabetes mellitus, dyslipidemia, cardiovascular 
disease, hypertension, as well as other physiological disorders, like liver 
dysfunction, musculoskeletal and respiratory disorders, and cancer, all have 
shown a close correlation with BMI and prevalence of increased body weight119. 
These comorbidities are exacerbated by the pro-inflammatory nature of the 
disease related to a dynamic immune response in adipocytes120. Customary 
ways to decrease the accumulation of adipose tissue are effective through long-
term efforts; however, finding inventive methods to attenuate adipose tissue may 
be instrumental to improving health prognosis for extreme cases. 
Directed efforts to understand the intricate changes in adipocyte 
morphology may hold the key to treating adipocyte dysfunction associated with 
obesity121. Various transcription factors have been identified that promote the 
differentiation of white adipocytes from adipocyte precursors. Peroxisome 
proliferator-activated receptor gamma (PPAR-γ) initiates lipid uptake and drives 
differentiation of adipocytes. In addition, sterol regulatory element-binding 
transcription factor 1 (SREBF1) promotes glucose metabolism and supports fatty 




associated with energy storage and metabolism, promote the maturation 
necessary for fully differentiated adipocytes. Once mature, these cells act as 
energy storage sites and modulate hormone signaling to a variety of tissues. 
Targeting adipogenesis has been on the forefront of obesity research, making 
downregulation of transcription factors that drive this process a natural mark for 
study124. 
In clinical studies, certain phytochemicals have been found to induce a 
catabolic state by activating energy sensor adenosine monophosphate-activated 
protein kinase (AMPK) promoting fatty acid oxidation and even adipocyte 
“browning” 125,126. Many phytochemicals have been shown to express anti-
inflammatory, antioxidative, anticancer, and anti-obesity affects127. Thorough 
investigation into a multitude of these compounds have yielded promising results 
to counter a variety of ailments, including pomegranate flavonoids, sulforaphane, 
turmeric, and quercetin. Each therapeutic phytochemical can vary in its 
mechanistic pathway or target ranging from increasing the efficiency of certain 
enzymes’ antioxidant activity, activating or preventing PPAR-γ and the 
inflammatory NF-kB pathway, to upregulating gene expressions associated with 
autophagy128.  
As mentioned, research investigating the effects of phytochemicals on 
adipose tissue development often illustrate changes in metabolism through 
AMPK. AMPK is a key regulator in cellular metabolism, known to heighten 




energy homeostasis is well evidenced through its stimulation of lipolytic 
mechanisms and its ability to improve insulin sensitivity130. Additionally, cyclic 
AMP-dependent protein kinase A (PKA) is a multifunctional protein that can 
initiate lipolytic events by phosphorylating hormone-sensitive lipases (HSL)130. 
Phosphorylated HSL translocates from the cytosol to stored triglycerides in the 
reservoir lipid droplet in adipocytes and exhibits an increase in hydrolytic 
activity131. Both PKA and AMPK have been shown to stimulate these hydrolytic 
events by HSL through different serine residues132. Upregulation of this pathway 
can inhibit normal differentiation processes associated with adipose tissue 
maturation. Several studies have confirmed fatty acid oxidation and mobilization 
can effectively halt adipogenesis when AMPK and HSL activity is promoted133.  
Zyflamend has shown efficacy in regulating inflammation and metabolism 
in cancer cells; perhaps in part due to the synergy expressed by its 
ingredients133-137. Although these mechanisms are not well understood, studies 
point to potential influence over genes regulating the cell cycle, autophagy, and 
apoptosis138. Furthermore, they have identified AMPK as responsible in shifting 
the metabolic dynamic in cancer cells, promoting apoptosis. As AMPK activity 
can support changes in metabolism through upregulation lipolysis, we wished to 
investigate how Zyflamend may activate this pathway in non-cancer cells, such 
as in adipocytes139. 
In this study, we examined the anti-adipogenic potential of Zyflamend and 




significantly decreased adipocyte differentiation in vitro by upregulating lipolysis 
activity and suppressing the activity of differentiation transcription factors PPAR-y 
and lipogenic enzymes fatty acid synthase and perilipin A. Additionally, 
upregulation of lipolytic mechanisms were noted. Furthermore, these processes 
were shown to be mediated by upregulation of JNK and increased activity of 
PKA-mediated HSL activity.  
2. Materials and Methods 
Chemicals and Reagents. Media, sera and trypsin for cell culture were 
purchased from Gibco (Thermo Fisher Scientific, Waltham, MA). Zyflamend was 
purchased from New Chapter Inc. (Brattleboro, VT). Primary antibodies and 
secondary antibodies were acquired from varying sources (Table 1). Chemical 
reagents such as dithiothreitol (DTT), percoll, digitonin, phenylmethylsulfonyl 
fluoride (PMSF), protease inhibitors cocktail, sodium deoxycholate, Triton X-100, 
ethylene glycol-bis-(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), sodium 
fluoride (NaF), Sodium phenylbutyrate (4-PBA), Hoechst 33258, propidium 
iodide, autophagy inhibitor (DBeQ), JNK inhibitor (SP600125), Thapsigargin, 
AICAR, TUDCA, HS38, H89, SB203580, STK1, Fasudil, and KT572 were 
acquired from Millipore-Sigma (Burlington, MA). Finally, AMPK inhibitor 





Cell Culture. Brown precursor cells were isolated from newborn wild type mouse 
by collagenase digestion as described previously, from brown fat pads140. 3T3-L1 
MBX (ATCC ® CRL-3242) cells were maintained in DMEM containing 25 mM 
glucose, 10% FBS, 50 U/ml penicillin and 50 μg/ml streptomycin. To induce cell 
differentiation, white, brown and 3T3-MBX pre-adipocytes were grown to 
confluence in culture medium containing 10% FBS. Confluent cells were then 
switched to differentiation media containing 10% FBS, 20 nM insulin and 1 nM 
triiodothyronine [T3] for 48 hours. Adipocyte differentiation was induced by 
treating cells for 48 h in differentiation medium further supplemented with 5 µM 
dexamethasone, 0.5 mM isobutylmethylxanthine, and 0.125 mM indomethacin 
(induction media). After induction, cells were returned to differentiation medium 
and exhibited a fully differentiated phenotype with accumulation of fat droplets. 
 
Zyflamend Treatment. Zyflamend was dissolved in DMSO at a concentration of 
800mg/ml for the stock solution.  Cells were treated with Zyflamend at the 
indicated concentration and for the indicated duration. Treatment was stopped by 
two washes with ice-cold phosphate buffer saline (PBS). Plates were then flash 
frozen in liquid nitrogen and stored at -80ºC until further analyses. 
 
Cytotoxicity Assay. Cytotoxicity assays were performed using sulforhodamine 
B (Millipore-Sigma) as previously described141. Briefly, 3T3-MBX pre-adipocytes 




indicated time. After the incubation, the cells were fixed with 17% trichloroacetic 
acid in PBS and cellular protein was stained for 10 min at room temperature with 
0.4% sulforhodamine B in 1% acetic acid solution. The plates were washed with 
water and dried, and the stain was dissolved in 0.2 mL 10 mM Tris (pH 9). 
Quantification of sulforhodamine B was carried out using the Synergy™ HTX 
Multi-Mode microplate reader (BioTek Instruments, Inc. Winooski, VT) at a 
wavelength of 540 nm. The relative plating efficiency of each cell line was 
determined by dividing the absorbance observed for a given treatment by the 
absorbance detected in the absence of treatment and expressed as a fold 
change. 
 
Quantification of Lipid Accumulation and Oil Red O Staining. On Day 12 of 
differentiation, cells were fixed with 10% PBS buffered formalin for at least 12 
hour at 4°C. Cells were stained for one hour with filtered oil red O solution (5 g/L 
in isopropyl alcohol), washed with distilled water, and examined using the Leica 
DMI8 inverted microscope (Leica Microsystems Inc. Buffalo Grove, IL).  
 
Western Blotting Analysis. Cells were lysed in radio-immunoprecipitation assay 
(RIPARIPA: 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% sodium dodecyl 
sulfate [SDS], 1% Triton X-100, 1% sodium deoxycholate, 5 mM EDTA, 1 mM 
NaF, 1 mM sodium orthovanadate and protease inhibitors) as we previously 




protein concentrations were determined using a bicinchoninic acid assay kit 
(Thermo Scientific Pierce BCA Protein Assay). Proteins (10-30 μg) were resolved 
by SDS-PAGE and transferred to PVDF membranes. Immunoblotting of lysates 
was performed with primary antibodies (Table 1), and after incubation with 
secondary antibodies, proteins were visualized using Luminata™ Western 
Chemiluminescent HRP Substrate (Millipore). Pixel intensities of immunoreactive 
bands were quantified using FluorChem Q Imaging software (Alpha Innotech 
Corp, San Leandro, CA). Data for phosphorylated proteins are presented as 
phosphorylation normalized to protein expression while total protein expression 
was normalized to β-actin as loading control.  
 
RNA Extraction, RT-PCR And Real-Time PCR. RNA was extracted from cells 
using TRIzol reagent (Invitrogen). The concentration of RNAs was determined 
using the NanoDrop® ND-1000 spectrophotometer (Thermo Scientific). Specific 
DNA products were generated with an RT-PCR system (high-capacity cDNA 
Synthesis Kit (Applied Biosystems). Primer sets are described in Table 2 and 
expression of different genes was assessed by quantitative real-time PCR using 
SsoAdvanced™ Universal SYBR® Green Supermix (BioRad) and the Bio-Rad 
CFX96™ system. Relative abundance of target gene mRNA was measured 






Annexin V Staining. Annexin V staining was performed as previously described 
with modification143. Briefly, 3T3-MBX pre-adipocytes were exposed to 
Zyflamend [for the indicated duration] then washed with PBS and resuspended in 
0.5ml of binding buffer (10 mM HEPES/NaOH, pH 7.5, 140 mM NaCl, and 
2.5 mM CaCl2) containing 5 μl of fluorescein isothiocyanate (FITC)-conjugated 
Annexin V (BD Pharmingen, San Diego, CA) and 10 μl of propidium iodide (PI) 
(Millipore-Sigma, Burlington, MA) for 10 min at room temperature in the dark. 
Cells (5,000) were then analyzed using the Guava® easyCyte Flow Cytometer 
(Millipore-Sigma). Intensities of fluorescence emitted by Annexin V-FITC 
(530 nm) and PI (585 nm) were collected on FL1 and FL3 channels, respectively. 
Both viable (negative for Annexin V and PI staining) and apoptotic cells (positive 
for Annexin V, but negative for PI staining) were quantified using CellQuest 
software (BD Biosciences, San Jose, CA). 
 
Cell Cycle Analysis. Cell cycle analysis was determined by examining the DNA 
content of cells stained with propidium iodide as previously described with 
modification144. Briefly, 3T3-MBX pre-adipocytes were exposed to Zyflamend [for 
the indicated duration] then washed with PBS and fixed in 70% ethanol for 
12hours at 4°C. After, cells were washed twice with cold PBS and then incubated 
in RNase solution in PBS (100 U/ml) for 30 min at 37°C. Cells were then 




4°C. Fluorescence was measured using the Guava® easyCyte flow cytometer 
and analyzed with ModFitLTTM cell cycle analysis program (Becton Dickinson).  
 
2-Deoxyglucose Uptake Assay. 2-Deoxyglucose uptake was determined using 
the colorimetric glucose uptake assay kit (Biovison INC., Milpitas, CA). Briefly, 
differentiated 3T3-MBX adipocytes were starved in low glucose (1mM) and 0% 
FBS media then treated with insulin for 30 minutes in the presence of 2-
deoxyglucose. Cells were then washed with ice-cold PBS and the accumulated 
2-Deoxyglucose was quantitated using the Synergy™ HTX Multi-Mode 
microplate reader. 
 
Statistical Analysis. Data are expressed as means +/- standard error of the 
mean (SEM). All statistical analyses were performed with JMP program (SAS 
Institute, NC) using an unpaired heteroscedastic two-tail Student's t test. 
Differences were considered significant at p<0.05 and highly significant at 
p<0.01. Single symbol (such as *) corresponds to p<0.05, while double (such as 
**) corresponds to p<0.01. 
3. Results 
In this study, we sought to investigate the effects of Zyflamend on lipid 
accumulation and differentiation of white adipocytes. 3T3-MBX white pre-




differentiation into fully mature white adipocytes was carried as described in the 
methods and outlined in Fig. 1B-C. On Day 12 of differentiation, cells were stained 
using the fat-specific dye Oil Red O to monitor lipid accumulation (Fig. 1C-E) To 
rule out off-target effects, control cells (0 ug/ml) were treated with the highest 
concentration of the vehicle DMSO (1.25 ul/ml). On day 12 of differentiation, these 
cells accumulated fat droplets and exhibited a fully differentiated phenotype with 
more than 85% of the cells containing fat droplets (Fig. 1D). In contrast, cells 
treated with Zyflamend resulted in a dose-dependent decrease in lipid 
accumulation and only a small percentage of cells (<10%) were able to accumulate 
fat.  Notably, cells treated with 1 mg/ml of Zyflamend exhibited blunted 
differentiation on Day 12 and were comparable to the non-differentiated cells at 
Day 1 of differentiation.  
To determine whether Zyflamend would alter adipogenesis of 3T3-MBX at 
this dose, we examined changes in lipid accumulation over a time course 
experiment over 12 days of differentiation. Consistent with the previous 
experiment, this dose significantly attenuated adipogenesis as judged by Oil red O 
staining and lipid accumulation (Fig. 2A-B).  
A growing body of literature indicates that Zyflamend exhibits anti-survival 
and pro-apoptotic effects on several cancer models135, 145-146. However, its effects 
on non-cancer cells have yet to be investigated.  To address this, we examined 
the effects of Zyflamend on pre-adipocyte proliferation using the sulforhodamine B 




in the presence of Zyflamend (200ug/ml) compared to DMSO (0.25ul/ml) as a 
vehicle control as shown in (Fig. 2C),  
We demonstrate that the expression of cyclins D1 and D2, which repress 
adipocyte differentiation, were significantly attenuated in Zyflamend treated cells 
in comparison to the control. The exception was D3, which did not show significant 
differences in response to Zyflamend. 
Expanding on these findings, we examined alterations in cell cycle and cell 
death in response to Zyflamend treatment. To examine whether attenuation of 
adipogenesis is caused by changes in cell proliferation, we also examined cell 
death of 3T3-MBX pre-adipocytes. These cells were cultured in the presence of 
Zyflamend (200ug/ml) or DMSO (0.25ul/ml) as a vehicle control for up to 48 hours. 
Cells treated with Zyflamend exhibited blunted proliferation. The intensity of the 
SRB staining reflected significant variation in the cell proliferation rate from a 12-
hour time point to 48 hours (p<0.05) between treated and non-treated cells.  
Patterns of differentiation correlate with expression of adipogenic 
markers: To further investigate the effects of Zyflamend on white adipose 
differentiation, we determined the expression of adipogenic markers fatty acid 
synthase (Fas), pyruvate carboxylase (PCB), perilipin, peroxisome proliferator-
activated receptor gamma (PPARγ), CCAAT-enhancer binding protein alpha 
(c/EBPα), adiponectin, and glucose transporter 4 (Glut 4). Consistent with previous 
report, FAS, PCB, c/EBP adiponectin, PPARγ exhibited a progressive increase in 




(Fig. 3A)147.  Conversely, cells treated with Zyflamend at a dose of 200 ug/ml 
exhibited blunted expression of these proteins throughout differentiation. In 
addition, we examined changes in other proteins associated with the non-
differentiated state of white adipocytes such as pre-adipocyte factor 1 (Pref1), α5 
integrin, fibronectin, and suppressor of cytokine signaling 9 (Sox9). The expression 
pattern of Pref1, α5 integrin, fibronectin, and Sox9 were comparable during the 
differentiation of control cells and exhibited a blunted expression by day 12 of 
differentiation. Cells treated with Zyflamend, on the other hand, maintained high 
levels of these proteins throughout differentiation. Consistent with protein 
expression, pref1 RNA was higher in Zyflamend treated cells compared to controls 
(Fig 3.B).  Next, the expression of several white fat specific genes was determined 
during differentiation of control and Zyflamend-treated cells. Consistent with the 
protein data, control cells exhibited a marked increase of mRNA in fas, ap2, 
resistin, c/ebp1a, and adiponectin. Zyflamend treatment abolished the expression 
of these genes. Additionally, changes in glucose uptake were also noted, with 
Zyflamend treatment modulating insulin response (Fig. 4). Taken together our data 
suggest that cells treated with Zyflamend exhibited attenuated differentiation, as 
indicated by lipid accumulation and changes in protein and mRNA expression.   
Zyflamend induces lipolysis in fully differentiated 3T3-MBX 
adipocytes: To investigate the molecular basis for the attenuated adipogenesis 
and decreased lipogenesis in Zyflamend-treated cells, we assessed the levels of 




phosphorylation and activation of AMPK in a dose dependent manner.  The 
increased AMPK phosphorylation and its activation were associated with a 
significant increase in ACC phosphorylation at Ser9, inhibiting its activity (Fig. 
5A-B). CPT1a expression was also reduced in Zyflamend treated-cells (Fig. 5A-
B).  
To examine whether the reduction in fatty acid synthesis was associated 
with increased lipolysis, we evaluated changes in energy storage markers. We 
conducted a dose response of Zyflamend and examined changes in protein 
expression of hormone-sensitive lipase (HSL) (Fig. 5C). As Zyflamend 
concentration increased, pHSL expression increased at serine sites 563, 565, 
and 660. PKA-mediated phosphorylation of HSL at S563 and S660 is essential 
for HSL translocation to lipid droplets and triacylglycerol hydrolysis148-149. During 
a time course experiment over 12 days, alterations in pHSL activity were noted 
between Zyflamend and DMSO. In the control, pHSL at S563 showed an 
increased and then proceeding decrease of activity, whereas Zyflamend 
treatment showed little phosphorylation until Day 12. Over the time course, 
phosphorylation of pHSL at S565, which is dependent on AMPK, was shown to 
decreased during normal differentiation activity with the DMSO control. 
Conversely, it remains at low activity during Zyflamend treatment. 
Phosphorylated HSL at S660 is shown to remain at low expression during the 
control treatment, but is significantly upregulated with Zyflamend treatment (Fig. 




differentiation of Zyflamend-treated cells compared to controls as judged by the 
phosphorylation of PKA substrates (Fig. 5G).  Collectively, this data indicates 
that the Zyflamend-induced lipolysis in 3T3-MBX is PKA dependent by 
upregulation of pHSL by S660. 
To determine if browning was a factor in changes of metabolic activity, we 
assessed the expression of the brown adipose marker UCP1. UCP1 protein was 
expressed in brown adipocytes (positive control) after 12 days of differentiation 
but not in Zyflamend-treated cells. Similarly, the expression of PRDM16 and 
BMP7 were highly expressed in brown adipocytes but not in white adipocytes 
treated with Zyflamend, confirming that Zyflamend treatment, while altering 
lipolysis and energy metabolism, does not induce browning of white 3T3-MBX 
adipocytes (Fig. 5I). 
We examined activation of MAP kinases during the course of 
differentiation of 3T3-MBX cells. Zyflamend exhibited a marked increase in JNK 
phosphorylation, particularly on Day 6 (Fig. 6A). Consistent with the activation of 
JNK, Zyflamend also increased the phosphorylation and activation of the JNK 
canonical downstream effectors, namely c-Fos and c-Jun. To further prove this 
hypothesis, we treated differentiating 3T3-MBX cells with Zyflamend along with 
specific inhibitors of PKA, p38 and JNK. We also used BML275 as a specific 
inhibitor for AMPK. As shown in Fig. 7, inhibition of JNK or PKA with SP600125 
and H89, respectively, reversed the effects of Zyflamend on differentiation as 




using SB203580 did not rescue the effects of Zyflamend on differentiation (data 
not shown). Inhibition of AMPK on the other hand, resulted in a moderate rescue 
of Zyflamend-induced attenuation of lipid accumulation in 3T3-MBX cells (Fig. 
7A-B). Together these data suggest that the impaired differentiation by 
Zyflamend is mainly mediated through the activation of PKA and JNK signaling 
pathways. 
The cross-talk between PKA and JNK mediates the anti-adipogenic 
potential of Zyflamend: Despite the large body of evidence implicating both 
PKA and JNK in stimulating lipolysis during adipocytes differentiation, little is 
known about the crosstalk between these two proteins in coordinating the 
hydrolysis of triglycerides and how this affects the overall differentiation process. 
To address this question, we used PKA and JNK inhibitors and examined 
changes in differentiation and triglyceride content (Fig. 7A). We also evaluated 
the effects of inhibiting both proteins on the overall differentiation process by 
examining changes in the expression of the differentiation markers; Fas, PCB, 
Perilipin, and Pref1 (Fig 7B).  Our study indicates that inhibition of PKA markedly 
attenuated the phosphorylation and activation of JNK while rescuing the effects 
of Zyflamend on the differentiation markers. On the other hand, while inhibition of 
JNK restored the expression of the differentiation markers in Zyflamend-treated 
cells, Zyflamend-induced PKA activation appears to decline (Fig. 7C-D). These 
results suggest that JNK is downstream target the PKA signaling and that our 




adipocyte through the activation of PKA, which in turns activates JNK. Finally, 
future studies are necessary to further determine the underlying mechanisms of 
JNK activation by PKA, such as examining the molecular mechanisms mediating 
the cross-talk between PKA and JNK. 
4. Discussion  
Zyflamend’s proven ability to activate AMPK and downregulate the NF-kB 
inflammatory pathway has identified it as a potent moderator for cancer. However, 
this study’s intent was to identify how Zyflamend treatment using an evidenced 
human dose equivalent may influence metabolism in non-cancer cells and 
determine its impact on cell metabolism. 
This study is the first of its kind to explore a direct relationship in Zyflamend 
treatment and metabolic research. We sought to investigate the effect of 
Zyflamend on adipocyte differentiation and determine the potential mechanisms 
involved. We discovered that Zyflamend significantly attenuated adipogenesis in 
3T3-MBX adipocytes by inhibiting lipid storage and upregulating lipolysis. We 
propose that these affects are due to Zyflamend’s ability to increase PKA and JNK 
signaling pathways. Considering these effects, we determine Zyflamend may have 
strong, natural therapeutic potential to address the development of adipose tissue, 
novel to metabolic research.  
The differentiation process of adipocytes relies heavily on cell signaling 
pathways that identify and respond to anabolic stimuli. As adipose tissue is a key 




bears great responsibility in managing growth, energy accessibility, and other 
metabolic processes. The ability for pre-adipocytes to fully differentiate and 
mediate energy storage in the form of triglycerides is essential for the development 
of obesity. Previous cancer research has established the efficacy of the human 
dose equivalent 200 ug/ml as an effective modulator in cancer studies. As this 
study is novel in design, our initial focus was to verify its efficacy in normal cells. 
First and foremost, we determined that 200 ug/ml was sufficient to promote 
changes in adipocytes differentiation. We noted attenuation of differentiation of 
3T3-MBX cells as judged by the abolished lipid accumulation, and decreased 
expression of differentiation markers. Due to changes in lipid metabolism, we also 
sought to verify Zyflamend’s ability to activate AMPK and determine this effect’s 
contribution to the shift in energy metabolism. Our observations support previous 
research, suggesting Zyflamend can effectively activate AMPK and decrease the 
activity of growth and survival pathways through AKT.  
Certain ingredients of Zyflamend previously studied exhibit the potential to 
activate AMPK and mediate adipogenesis. To name a few ginger, turmeric, and 
green tea have been shown to disrupt the onset of obesity, noting their ability to 
inhibit adipose expansion and suppress differentiation via activation of AMPK 
through food derived components150. Similar studies have noted the impact of 
Turmeric on activation of lipolysis through adipose triglyceride lipase and hormone 
sensitive lipase151. This activity can stunt the process of differentiation by 




mechanisms that promote growth. The ability for the ingredients of Zyflamend to 
mobilize stored triglycerides supports our findings without the necessity of doses 
such 500g/kg body weight as evidenced in previous literature151. As discussed, 
Zyflamend exhibits unique synergistic affects improving the efficacy of the 
ingredients’ biological reactions at relatively low quantity of the components 
promoting the translatability of our study. Furthermore, Zyflamend increased the 
activity of HSL at S660, suggesting PKA may be mediating lipolysis activity.  
We were able to determine the effects of Zyflamend increasing lipolytic 
mechanisms in white pre-adipocytes were not due to the upregulation and 
expression of a brown phenotype. We determined that Zyflamend inhibited UCP1 
expression, suggesting that the metabolic shift was independent of browning 
mechanisms. Currently, investigations to increase rates of brown or beige 
adipocytes has led the forefront of obesity research. The thermogenic potential of 
this phenotype has supported many research efforts to increase natural energy 
expenditure. As this area of research continues to grow, we propose exploring 
other biological avenues of obesity interventions. Previous research investigating 
the metabolomic potential of Zyflamend has previously reported attenuation of 
adipose tissue in C57BL/6 mice treated with Zyflamend204. However, this study did 
not differentiate the prevalence of brown adipose tissue, suggesting our findings 





We sought to determine how AMPK, JNK, and PKA activation induced by 
Zyflamend influenced the process of differentiation. Using specific inhibitors of 
each, we observed that inhibition of these key regulators impacted the overall 
effects of Zyflamend on the differentiation process. However, inhibition of JNK 
through SP600125 was able to rescue the effects of Zyflamend most significantly 
and promote normal adipogenesis. This outcome suggests it is Zyflamend’s ability 
to activate JNK that prevents maturation of 3T3-BMX pre-adipocytes. 
This treatment attenuated adipogenesis and significantly decreased the 
uptake and storage of glucose and lipids. Some studies have published similar 
effects on adipogenesis through some of the components of Zyflamend. Previous 
research determined the effects of curcumin as suppressing differentiation by 
promoting apoptosis of 3T3-L1 adipocytes151. In our investigations, the compound 
Zyflamend was able to suppress these effects without significantly altering cell 
proliferation rates.  
We observed increased activity of HSL at S660. As we described, HSL as 
S660 is activated not through AMPK, but through upstream activator PKA.  This 
has yielded rare insight into the complex interactions occurring from Zyflamend 
treatment. Other studies have yet to observe this interaction between PKA activity. 
When exploring how PKA inhibitor H89 influenced the reaction of Zyflamend 
treatment during adipogenesis, we observed a stronger rescue reaction from 
inhibition of PKA in comparison to AMPK inhibitor BML275. This suggests that 




We aimed to determine the key regulator attenuating the adipogenesis we 
observed in 3T3-MBX pre-adipocytes treated with Zyflamend. We determined that 
JNK activity was particularly upregulated in these cells. Although the mechanisms 
that promote this activation have yet to be explored, our study evidenced JNK has 
having a potent lipolytic role. By exploring how JNK inhibitor SP600125 interacted 
with the effects of Zyflamend, we observed a rescue effect suggesting JNK 
activation is essential for Zyflamend’s effect on abolishing lipid storage and 
differentiation. There is reference to the lipolytic action of JNK in various studies; 
although we have yet to determine what mechanisms may be driving this force, 
previous literature hypothesizes autophagy and ER stress. 
This study provides novel insight into the potential of phytochemical 
interventions in metabolic disease. Despite this study being novel within the current 
literature, future studies are warranted to investigate the relationship between JNK 
activation and the differentiation process of adipocytes. The transition towards 
abandoning conventional pharmaceutical methods and embracing holistic and 
synergistic bioactive nutrient therapies presents a transformative paradigm to 
disease research. This study was designed to incorporate a shift in perspective 
utilizing nutrition basic science research to establish a counterargument to more 
traditional therapeutic approaches. Zyflamend has already established itself in 
previous cancer research to provide therapeutic potential when more traditional 
strategies are exhausted. In this study, we demonstrated the plausibility of future 




mechanisms at play are required before solidifying Zyflamend’s role in obesity 












 Recent studies have demonstrated that Zyflamend triggers a dose-
dependent anti-lipogenic response in prostate cancer cells through the activation 
of the energy sensor AMP-activated protein kinase (AMPK)131, 133, 138, 147. The 
findings from this study suggest that Zyflamend-induced PKA activation may alter 
lipid metabolism in adipocytes and dysregulate adipocyte differentiation. Adipocyte 
differentiation is a complex process that requires integration of a multitude of 
stimuli including nutrients and hormones and is often marked by the increased 
expression of several genes involved in adipogenesis and lipid accumulation27. In 
this study, we sought to investigate the effects of Zyflamend on lipid accumulation 
and differentiation of white adipocytes.  Several factors may explain the decreased 
differentiation of Zyflamend-treated cells such as increased cell death, elevated 
lipolysis, reduced lipogenesis, loss of contact inhibition, inhibition of clonal 
expansion, transdifferentiation into brown-like adipocytes, etc. Thus, we conducted 
a detailed analysis of the effects of Zyflamend on pre-adipocyte proliferation, cell 
cycle, cell death, and differentiation. Together with our findings on PKA, these 
results suggest that PKA and/or JNK signaling pathways are what potentially 





2. Future Perspectives 
 As Zyflamend has been shown across the literature to be a modulator of 
inflammation and regulator of metabolism in cancer cells, future research should 
continue to investigate and explore the effects of Zyflamend treatments against 
non-cancer cells. This study explored the potential of Zyflamend to regulate 
normal metabolic function within adipocytes and provided evidence of its 
potential as a modulator of adipocyte differentiation. These methods will help to 
elucidate the mechanisms that regulate this process through upregulation of JNK 
and PKA-mediated lipolysis. However, the necessity to further determine the 
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Table S1: List of primers used to quantitate the mRNA levels of markers of 
differentiation 
 































Table S1: List of primary antibodies and conditions of use. 
Table S2: List of primary antibodies and conditions of use. 
 
Antibodies   Source Host Dilution 
ACC Cell Signaling Technology Rabbit 1:2,000 
Adiponectin Abcam Rabbit 1: 1,000 
AMPK Cell Signaling Technology Rabbit 1:5,000 
BMP7 Santa Cruz Biotechnology Mouse 
1:1,000 
C/EBP Santa Cruz Biotechnology 
Mouse 1:1,000 
c-Fos Santa Cruz Biotechnology 
Mouse 1:1,000 
c-Jun Santa Cruz Biotechnology 
Mouse 1:1,000 
CPT1a Abcam Mouse 1: 1,000 
Cyclin D1 Cell Signaling Technology Rabbit 1:5,000 
Cyclin D2 Cell Signaling Technology Rabbit 1:2,500 
Cyclin D3 Cell Signaling Technology Rabbit 1:5,000 
Fas Santa Cruz Biotechnology Mouse 1:5,000 
Fibronectin Santa Cruz Biotechnology Mouse 1: 1,000 
Glut4 Santa Cruz Biotechnology 
Mouse 1:5,000 
HSL Cell Signaling 
Technology Rabbit 1:1,000 
JNK1/2 Santa Cruz Biotechnology 
Mouse 1:1,000 
MnSOD Santa Cruz Biotechnology Mouse 1:2,500 
p38 Santa Cruz Biotechnology 
Mouse 1:1,000 
PCB Santa Cruz Biotechnology 
Mouse 1:5,000 







Table S2 Continued 
 
Antibodies   Source Host Dilution 
Phospho-ACCS9 Cell Signaling Technology Rabbit 1:1,000 
Phospho-AMPKT172 Cell Signaling Technology Rabbit 1:2,500 
Phospho-c-JunS63 Santa Cruz Biotechnology 
Mouse 1:1,000 
Phospho-HSLS563 Cell Signaling Technology Rabbit 1:1,000 
Phospho-HSLS565 Cell Signaling 
Technology Rabbit 1:1,000 
Phospho-HSLS660 Cell Signaling 
Technology Rabbit 1:1,000 
Phospho-JNK1/2T183/Y185  Santa Cruz Biotechnology 
Mouse 1:1,000 





Technology Rabbit 1:5,000 
PPARγ Cell Signaling Technology Rabbit 1:1,000 
PRDM16 Abcam Mouse 1: 2,000 
Pref 1 Cell Signaling Technology Rabbit 1:1,000 
Sox9 Santa Cruz Biotechnology 
Mouse 1:1,000 
UCP1 Santa Cruz Biotechnology Mouse 1:5,000 
α5 Integrin Santa Cruz Biotechnology Mouse 1: 1,000 








Figure 1. Dose Dependent Effect of Zyflamend on adipocytes 
differentiation. A) Composition of Zyflamend. B) A Schematic illustration of the 
differentiation procedure. C) 3T3-MBX were differentiated in the presence of 
increasing doses of Zyflamend for 12 days. Cells were fixed and stained with oil 
red O. C) Oil red O-stained and (D) phase contrast  mages of non-differentiated 
(day 1) and differentiated adipocytes (day 12). Scale bar: 200 μm Images on the 
right panel are magnification of the boxed regions. D) Oil Red O stain was 
extracted and its absorbance (520 nm) was quantitated.  Graph represents data 
from six independent experiments, and data are expressed as mean + SEM.  
*p<0.05, **p<0.01 indicate significant difference between non-treated and 
Zyflamend treated cells.  E.) Dose Dependent Effect of Zyflamend on adipocytes 




Figure 2. A physiologically relevant dose of Zyflamend inhibits adipocytes 
differentiation and glucose uptake. A) 3T3-MBX pre-adipocytes were treated 
with DMSO or 200 ug/ml of Zyflamend and differentiated as described in the 
Methods section.  At different days of differentiation, cells were fixed and stained 
with oil Red O, and then triglyceride content was quantitated 
spectrophotometrically (520 nm) quantitated (B). Graph represents data from six 
independent experiments, and data are expressed as mean + SEM.  *p<0.05, 
**p<0.01 indicate significant difference between the indicated time and day one 
of differentiation. †p<0.05, ††p<0.01 indicate significant difference between 
Zyflamend and control (DMSO) treated cells.  C) 3T3-MBX pre-adipocytes were 
treated with DMSO or 200 ug/ml of Zyflamend for the indicated time and cell 
survival was assessed using the sulfide-reducing bacteria (SRB) cytotoxicity 
assay as detailed in the Methods section. Bar graphs represent the intensity of 
SRB staining reflective of the cell number and presented as means + SEM. 
*p<0.05, **p<0.01 indicate significant difference between cell proliferation rate at 
the indicated time point and 12hours.  †p<0.05, ††p<0.01 indicate significant 
difference between non-treated and Zyflamend treated cells (50 ug/ml–500 
ug/ml). D) Assessment of DNA content and cell cycle analysis in 3T3-MBX pre-
adipocytes treated with DMSO or Zyflamend. Representative histogram 
distributions for each treatment are shown. E) Bar graphs represent the 
percentages of cells in each phase of the cell cycle which were estimated using 




three independent experiments. *p<0.05, **p<0.01 indicate significant difference 
the indicated concentration and control cells treated with the vehicle DMSO. F) 
Immunoblots of cell cycle regulators cyclins D1, D2, and D3 in cells treated with 
200 ug/ml of Zyflamend at various stages of differentiation. Representative 
Immunoblots from three independent experiments are shown. G) Bar graphs 
represent Cyclin D1, D2 and D3 normalized to β-Actin as a loading control and 
presented as means + SEM. *p<0.05, **p<0.01 indicate significant difference the 
indicated time point and day 1 of differentiation. †p<0.05, ††p<0.01 indicate 
significant difference between Zyflamend and control (DMSO treated) cells. H-I) 
50% confluent cells were treated with increasing concentrations of Zyflamend (50 
ug/ml–500 ug/ml), and then labelled with Annexin V-FITC and 7-AAD. 
Representative dot plots are shown. Annexin V positive and /7-AAD negative 
cells (lower right quadrants) represent early stages of apoptosis, whereas cells 
that are positive for both Annexin V and 7-AAD (upper right quadrants) are in late 
stage of apoptosis. Bar graphs represent live, early, and late apoptotic cells are 
presented as means +/- SEM of at least three independent experiments. *p<0.05, 
**p<0.01 indicate significant difference the indicated concentration and control 










Figure 3. Zyflamend inhibits differentiation of 3T3-MBX pre-adipocytes. A) 
Immunoblots of adipogenic markers in 3T3-MBX cells treated or non-treated with 
Zyflamend (200ug/ml) at varying stages of differentiation. Lysates were blotted 
for β-actin to control for loading.  Representative Immunoblots from three 
independent experiments are shown. B) Bar graphs represent the indicated 
protein normalized to β-Actin as means + SEM. *p<0.05, **p<0.01 indicate 
significant difference between indicated time points and day 1 for each cell type. 
†p<0.05, ††p<0.01 indicate significant difference between Zyflamend and control 
(DMSO) treated cells. C) Quantitative (q) RT-PCR of Fas, Pref1, Resistin, Ap2, 
Adiponectin, Cebp1a, Pparg, Perilipin, Sreb1c, Fadb4, Visfatin, and Cidea mRNA 
levels in control and Zyflamend (200 ug/ml) treated cells at various days of 
differentiation. Data are normalized to 18S ribosomal RNA (18S rRNA). Results 
are representative of three independent experiments and data are expressed as 
mean +/- SEM. *p<0.05, **p<0.01 indicate significant difference between 
indicated time points and day 1 for each treatment.  †p<0.05, ††p<0.01 indicate 













Figure 4. Zyflamend inhibits glucose uptake. 3T3-MBX pre-adipocytes were 
treated with DMSO or 200 ug/ml of Zyflamend and differentiated as described in 
the methods section.  On day 12, cells were starved overnight in low glucose (1 
mM) and 0% FBS media then treated with insulin for 30 minutes in the presence 
of 2-deoxyglucose. 2-doxyglucose uptake was quantified and presented as 
means +/- SEM of three independent experiments. Graph represents data from 
four independent experiments, and data are expressed as mean +/- SEM.  
*p<0.05, **p<0.01 indicate significant difference between the insulin treated and 
non-treated cells. †p<0.05, ††p<0.01 indicate significant difference between 





Figure 5. Zyflamend inhibits lipogenesis and induces lipolysis in fully 
differentiated 3T3-MBX adipocytes. Total lysates from fully differentiated 3T3-
MBX adipocytes treated with the indicated concentrations of Zyflamend (0-400 
ug/ml) for 24 hrs were immunoblotted for markers of lipogenesis (A-B) and 
lipolysis (C-D). Representative Immunoblots from three independent experiments 
are shown. B-D) Bar graphs represent pAMPKT172/AMPK, Fas/β-Actin, 
pACCS79/ACC, CPT1α/β-Actin, pAKTS473/AKT, pGSKS9/GSK, pHSLS563/HSL, 
pHSLS565/HSL, pHSLS660/HSL, and HSL/ β-Actin as means + SEM. *p<0.05, 
**p<0.01 indicate significant difference between indicated concentration of 
Zyflamend and control (0) untreated cells. E-F) Immunoblots of pHSLS563, 
pHSLS565, pHSLS660, and HSL in 3T3-MBX cells treated or non-treated with 
Zyflamend (200 ug/ml) at varying stages of differentiation. Representative 
Immunoblots from three independent experiments are shown. F) Bar graphs 
represent pHSLS563/HSL, pHSLS565/HSL, pHSLS660/HSL, and HSL/ β-Actin as 
means + SEM. *p<0.05, **p<0.01 indicate significant difference between 
indicated time points and day 1 for each treatment. †p<0.05, ††p<0.01 indicate 
significant difference between Zyflamend and control (DMSO) treated cells. G-H) 
Immunoblots of phosphorylated PKA substrate in 3T3-MBX cells treated or non-
treated with Zyflamend (200ug/ml) at varying stages of differentiation. 
Representative Immunoblots from three independent experiments are shown.  H) 
Bar graphs represent phosphorylated PKA substrate /β-Actin as means + SEM. 




and day 1 for each treatment. †p<0.05, ††p<0.01 indicate significant difference 
between Zyflamend and control (DMSO) treated cells.  I) Immunoblots of UCP1, 
prdm16, and BMP7 in 3T3-MBX cells treated or non-treated with Zyflamend 
(200ug/ml) at varying stages of differentiation. Primary inguinal fully differentiated 















Figure 6. Zyflamend activates JNK and PKA during the differentiation of 
3T3-MBX adipocytes.  Total cell lysates from control and Zyflamend treated 
cells at various stages of differentiation were immunoblotted for (A) 
phosphorylated p38, JNK, c-Jun and their respective unphosphorylated proteins, 
c-Fos. Samples were also blotted for β-Actin as a loading control. Representative 
immunoblots from three independent experiments are shown. B) Bar graphs 
represent pp38T180/Y182/p38, pJNKT183/Y185/JNK, pc-JunS63/c-Jun, and c-Fos/β-
Actin as means + SEM. p<0.05, **p<0.01 indicate significant difference between 
indicated time points and day 1 for each treatment. †p<0.05, ††p<0.01 indicate 





Figure 7. Inhibition of PKA and JNK abrogates the effects of Zyflamend on 
differentiation A) Oil red O-stained images of non-differentiated (day 1) and 
differentiated adipocytes (day 12) treated or non-treated with AMPK (BML-275), 
JNK (SP600125) or PKA (H89) inhibitors. B) Oil Red O stain was extracted and 
its absorbance (520 nm) was quantitated.  Graph represents data from at least 
six independent experiments, and data are expressed as mean +/- SEM.  
*p<0.05, **p<0.01 indicate significant difference between non-treated and 
Zyflamend treated cells.  †p<0.05, ††p<0.01 indicate significant difference 
between cells treated with the indicated inhibitor together with Zyflamend and 
cells treated with Zyflamend only. C) Phase contrast images of non-differentiated 
(day 1/D1) and differentiated adipocytes (day 12/D12) treated or non-treated with 
SP600125 or H89. Images in the right panel are magnification of the boxed 
regions. Scale bar: 200 μm.  D-G) Immunoblots of adipogenic markers in 3T3-
MBX cells treated or non-treated with Zyflamend (200ug/ml) with or without PKA 
inhibitor (H89; D) or JNK inhibitor (SP600125; F). Lysates were blotted for β-actin 
to control for loading.  Representative Immunoblots from three independent 
experiments are shown. E-G) Bar graphs represent the indicated protein 
normalized to β-Actin as means +/- SEM. *p<0.05, **p<0.01 indicate significant 
difference between day 12 and day 1 of differentiation for each treatment. 






Figure 2: Inhibition of PKA and JNK abrogates the effects of Zyflamend on 
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